Medtronic’s diabetes assistant shows better outcomes with Artificial Intelligence

Powered by AI, Medtronic’s Sugar.IQ diabetes assistant shows better outcomes

By Arundhati Parmar

On Friday, a diabetes expert described Medtronic’s Sugar.IQ diabetes assistant as a “key differentiator” among all the continuous glucose monitoring systems available in the market.

On Monday, Dublin-Ireland based Medtronic announced the results of a study that showed that patients using the Sugar.IQ diabetes assistant spent more time within a designated blood glucose range compared with those that didn’t.

Along with Medtronic, IBM Watson also presented data on its machine-learning algorithm and its ability to predict low-glucose events within a one-to-four-hour window.